EP4673115A1 — Liquid formulation comprising trilostane
Assigned to Norbrook Laboratories Ltd · Expires 2026-01-07 · 0y expired
What this patent protects
The present disclosure relates to a liquid formulation comprising: (a) trilostane or a pharmaceutically acceptable salt thereof; (b) a viscosity modifier; (c) an organic co-solvent; and (d) water; wherein the organic co-solvent has at least one hydroxy group, and is water- solubl…
USPTO Abstract
The present disclosure relates to a liquid formulation comprising: (a) trilostane or a pharmaceutically acceptable salt thereof; (b) a viscosity modifier; (c) an organic co-solvent; and (d) water; wherein the organic co-solvent has at least one hydroxy group, and is water- soluble or water-miscible. Also described are uses of the liquid formulation and methods involving the liquid formulation for the treatment or prevention of Cushing's disease or syndrome. A kit of parts including the liquid formulation is also described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.